|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Regulation: OK After All
Author(s)Kevin Gopal
London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.
Advertisement
Articles in this issue
over 24 years ago
Internet DTC - Minding Your P's & Q'sover 24 years ago
Regulation: Two-Track Planover 24 years ago
Policy: Tectonic Shiftover 24 years ago
Liberated?over 24 years ago
A Matter of Tasteover 24 years ago
Partnerships: Bargaining Biotechsover 24 years ago
Pediatric Mandateover 24 years ago
Genentech's Passion for PatientsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
